Recruiting

Observational Study

Sponsor:

Stanford University

Code:

NCT03458520

Conditions

Soft Tissue

Lymphoma

Osteosarcoma

Eligibility Criteria

Sex: All

Age: 0 - 40

Healthy Volunteers: Not accepted

Interventions

PET/MR imaging

MR imaging

PET/CT imaging

Study Details

Brief summary:

The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.

Conditions

Soft Tissue

Lymphoma

Osteosarcoma

Study ID

NCT03458520

Start date

Feb 1, 2018

Status verified date

Feb, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 40

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor.
  • We might also include some patients with leukemia if there is concern for a focal lesion in any of their organs.
  • Participant's parents (if participant is under 18) or the participant (if participant is 18 years or older) must willingly give written informed consent prior to any image transfer to the image registry.

Exclusion Criteria:

  • Patient has contraindications for MRI or PET/MR. This includes patients with cardiac pacemakers or intracranial vascular clips as well as patients with a blood glucose level > 200 mg/dl.
  • Lack of parental permission (if participant is younger than 18) or lack of informed consent (if participant is at least 18 years of age).
  • Patient has a CNS primary tumor.
  • Pregnant women and fetuses

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Image Registry

patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)

Interventions

PET/MR imaging

undergo PET/MR imaging

MR imaging

Undergo MR imaging

PET/CT imaging

Undergo PET/CT imaging

Primary outcome measure

  • Number of tumors [ Time Frame: up to 12 months ]

Central Contacts and Locations

Central contacts

Anne Muehe

650-720-8601amuehe@stanford.edu

Locations

Stanford University, School of Medicine

Recruiting

Palo Alto, California, United States, 94304

Contacts

Anne Muehe

650-720-8601amuehe@stanford.edu

Principal Investigator:

Heike Daldrup-Link, MD

More Information

Sponsor

Stanford University

Last update posted

Feb 9, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Stanford University on 2026-02-09.